Ananda Basu, MD
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1821062647
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,471 of the $7,250 with a category attached, or 89.3%. 9 manufacturers reported payments, led by Dexcom, Inc. at 49.3% of the total. Reporting peaked in 2021 at $2,678 and has fallen 84.6% since, to $413 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AL, where the typical reported total is $6,650.
Across 15 payments — averaging $483.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$4K
- Intercept Pharmaceuticals, Inc.$2K
- Zealand Pharma US, Inc.$800
- Medtronic$378
- Inspire Medical Systems, Inc.$131
- Novo Nordisk$112
- plus $159 from 3 others
Across 6 payments — averaging $1247.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$7K
What the payments were for
- Speaking & faculty fees$6,47189%
- Travel & lodging$120%
- Food & beverage$76711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 2 | $3,571 |
| Intercept Pharmaceuticals, Inc. | 1 | $2,100 |
| Zealand Pharma US, Inc. | 1 | $800 |
| Medtronic | 3 | $378 |
| Inspire Medical Systems, Inc. | 1 | $131 |
| Novo Nordisk | 3 | $112 |
| Abbott | 2 | $71 |
| Madrigal Pharmaceuticals | 1 | $54 |
| BETA Bionics, Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$2,678
- ZEGALOGUE$800
- MINIMED 780G$365
- Inspire$131
How this compares
$7,250 in reported general payments places this provider in the 50th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 65 | $71,640 |
| MounjaroTirzepatide | 58 | $62,911 |
| JardianceEmpagliflozin | 31 | $29,888 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $16,515 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $13,322 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $4,866 |
| Novolog FlexpenInsulin Aspart | 16 | $4,307 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,522 |
| Pregabalin | 18 | $190 |
| Atorvastatin Calcium | 14 | $97 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $112 | $71,64065 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Birmingham
- Ralph TeagueBirmingham$487K
- William GarveyBirmingham$421K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
- Fernando OvalleBirmingham$15K
- Jennifer SohnBirmingham$14K
- Jorge PinoBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.